What Is the Best ED Medication for Men With Heart Disease?
No trial ranks the four tablets in men with heart disease. The labels and large registry studies do show who should avoid them, who needs a cardiology check first and what the alternatives are.
The short version
- Nitrates and riociguat rule out every ED tablet; in a Swedish cohort of men with coronary disease on nitrates, adding a PDE5 inhibitor was linked to higher mortality (HR 1.39).123
- Labels do not recommend the tablets soon after a heart attack (90 days for tadalafil, 6 months for the others) or with unstable angina.2345
- After a first heart attack, men dispensed ED treatment had 33% lower mortality in a 43,145-man registry study, but it is observational and cannot show cause.6
- No study ranks the four tablets for heart safety; the Princeton IV consensus says to treat men with ED as at risk for cardiac events until shown otherwise.7
No ED tablet is the best choice for every man with heart disease, and no trial has ranked the four against each other in cardiac patients. What the labels and studies do show is who should not take any of them (anyone on a nitrate or riociguat), who needs a cardiology check first (recent heart attack, unstable angina, heart failure, very high or low blood pressure), and that in stable coronary disease the tablets have not been linked to harm in large Swedish registry studies.23458 The decision is made with a clinician who knows the heart history, not from a ranking.
This guide sets out the label limits for each tablet, the observational evidence, and the alternatives, so a reader can walk into that conversation prepared.
Can men with heart disease take ED medication at all?
Often yes, once the heart condition is stable and the medicine list has been checked. The Princeton IV consensus panel (a multispecialty group of urologists and cardiologists, 2024) advises treating men with ED as at risk for cardiac events until shown otherwise, and covers how to use oral PDE5 inhibitors in men with cardiovascular disease.7 Every label starts from the same question: is sexual activity itself advisable given the man's cardiovascular status? Sildenafil, tadalafil and vardenafil labels say these drugs should not be used in men for whom sexual activity is inadvisable because of their heart condition, and the avanafil label says the same.2345
Two things are absolute. Nitrates in any form (nitroglycerin tablets, sprays, patches, isosorbide) must not be combined with these tablets, and neither must guanylate cyclase stimulators such as riociguat.2345 The avanafil label also names vericiguat, a heart failure medicine.5
What do the labels say about each heart condition?
The labels group cardiac patients into those the drug has not been studied in. Each manufacturer words its list differently, so the table is a summary of the label text, not a head-to-head comparison.
| Situation | Sildenafil (Viagra) | Tadalafil (Cialis) | Vardenafil | Avanafil (Stendra) |
|---|---|---|---|---|
| Heart attack | No controlled data within 6 months2 | Not recommended within 90 days3 | Not recommended within 6 months4 | Not recommended within 6 months5 |
| Stroke or life-threatening arrhythmia | No controlled data within 6 months2 | Stroke within 6 months, or uncontrolled arrhythmia3 | Within 6 months4 | Within 6 months5 |
| Unstable angina | No controlled data2 | Not recommended; also angina during intercourse3 | Not recommended4 | Not recommended; also angina with intercourse5 |
| Heart failure | Cardiac failure: no controlled data2 | NYHA class 2 or greater in last 6 months3 | Severe cardiac failure4 | NYHA class 2 or greater5 |
| Blood pressure limits | Below 90/50 or above 170/1102 | Below 90/50 or uncontrolled hypertension3 | Systolic below 90 or above 170/1104 | Below 90/50 or above 170/1005 |
| Nitrate wait in an emergency | Label says it is unknown whether nitrates are safe even at 24 hours2 | At least 48 hours3 | No effect seen when nitroglycerin followed vardenafil 20 mg by 24 hours4 | At least 12 hours5 |
The tadalafil label points out that men with cardiovascular disease were not included in its clinical trials.3 That is true of most ED drug trials, which is why the cardiac evidence below comes from registries rather than randomized studies.
Is one tablet safer for the heart?
The studies do not say so. The Swedish registry papers group all PDE5 inhibitors together and do not compare individual drugs for safety. A 2017 nationwide cohort of 43,145 men after a first heart attack found that the 7.1% who were dispensed ED treatment had 33% lower mortality (adjusted hazard ratio 0.67) and a 40% lower risk of heart failure hospitalization than those who were not.6 A 2021 study of 16,548 men on PDE5 inhibitors and 1,994 on alprostadil, all with prior heart attack or revascularization, found lower mortality with PDE5 inhibitors (hazard ratio 0.88).8
These are observational analyses. The authors of the 2021 paper state the data do not allow causality or clinical benefit to be inferred, and men who get ED treatment may simply be healthier or better followed.8 What the findings can fairly support is narrower: in stable coronary disease, using a PDE5 inhibitor was not associated with the harm that people fear. The Princeton IV panel also notes possible cardioprotective effects but is describing emerging evidence, not a reason to take a tablet.7
The same Swedish group found the opposite for the nitrate combination. Among 55,777 men with stable coronary disease on nitrates, the 5,710 who also used a PDE5 inhibitor had higher mortality (hazard ratio 1.39) and more heart attacks (1.72), which the authors read as a possible hazard and an argument against the combination.1 That study also cannot prove cause, but it matches what every label already says.
What about alprostadil and other options?
Alprostadil is the non-tablet alternative, given by injection or urethral suppository, and it is the main option for men who take nitrates daily. In the 2021 cohort, men on alprostadil had higher mortality than men on PDE5 inhibitors, but those groups differed in health and in why they were chosen for each drug, so the result does not mean alprostadil is harmful.8 The AUA guideline treats ED as a prompt to look at overall health and lists these options for men who cannot take tablets.9 A cardiologist can also say whether the heart is stable enough for sexual activity before any treatment starts.7
How should a man with heart disease choose?
- On a nitrate or riociguat: no tablet in this class, and an alternative route is the conversation to have.2345
- Heart attack, stroke or arrhythmia in recent months, or unstable angina: stabilize first and ask the cardiologist before any ED treatment.235
- Stable coronary disease, no nitrates: a clinician may start a tablet at a low dose; the registry data do not rank them.8
- Also on blood pressure medicine: see our guide to ED medication with high blood pressure, which sets out the interaction figures by drug class.
- Also managing diabetes or aged over 60: read ED medication for men with diabetes and men over 60.
What should you ask before getting a prescription?
- Do I take any nitrate, in any form, or riociguat or vericiguat?25
- Is my heart condition stable enough that sexual activity is advisable?7
- When was my last heart attack, stroke or arrhythmia, and does that fall inside the label's 90-day or 6-month limits?34
- Is my blood pressure controlled, and which dose should I start with?25
- What symptoms (chest pain, fainting, an erection longer than four hours) mean stop and seek emergency care?23
A telehealth service helps only if its screening asks these questions. Our guide to whether online doctors can prescribe Viagra covers what a proper check includes.
What this article does not cover
It covers FDA-approved oral tablets. Compounded versions are not FDA-approved.10 The registry studies are observational and Swedish, drug names are grouped, and none of the evidence here replaces an assessment by a cardiologist or prescriber who has the full history. Chest pain, fainting or shortness of breath at any time needs emergency care.
Frequently asked questions
What is the best ED medication for heart patients?
No label or trial names one best drug for heart disease. A prescriber chooses based on the heart condition, blood pressure and other medicines, and nitrates rule out every tablet.
Is Viagra safe for heart patients?
The Viagra label says it should not be used where sexual activity is inadvisable because of cardiovascular status, and lists recent heart attack, stroke, unstable angina and cardiac failure as groups with no controlled data. Nitrates are never allowed.
Can you take ED pills after a heart attack?
Labels say not within 90 days for tadalafil and within 6 months for the other tablets. After that, a cardiologist decides; a Swedish registry linked ED treatment after a first heart attack to lower mortality, though not as proof of benefit.
Can heart patients take Cialis?
Sometimes. The Cialis label does not recommend it after a heart attack in the last 90 days, with unstable angina, or with class 2 or greater heart failure in the last 6 months, and never with nitrates.
What can men on nitrates use instead of ED pills?
Alprostadil by injection or suppository is the usual non-tablet option, and the AUA guideline lists others. A clinician who knows the heart history should guide the choice.
Related reading
- ED Pills Non Prescription: What Is Sold and What the FDA Says
- Where Can You Buy ED Pills Safely?
- ED Medication Online: What You Can Get and How to Do It Safely
- Tadalafil Online: How a Safe Prescription Works
- The best ED treatments of 2026, compared side by side
- Sildenafil vs tadalafil vs vardenafil: how they differ
Sources
- Trolle Lagerros Y, et al. Risk of death in patients with coronary artery disease taking nitrates and phosphodiesterase-5 inhibitors. J Am Coll Cardiol. 2024. PubMed.
- Pfizer. VIAGRA (sildenafil citrate) prescribing information. DailyMed, U.S. National Library of Medicine.
- Eli Lilly. CIALIS (tadalafil) prescribing information. DailyMed, U.S. National Library of Medicine.
- Teva Pharmaceuticals USA. Vardenafil hydrochloride tablets prescribing information. DailyMed, U.S. National Library of Medicine.
- Metuchen Pharmaceuticals. STENDRA (avanafil) prescribing information. DailyMed, U.S. National Library of Medicine.
- Andersson DP, et al. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart. 2017. PubMed.
- Köhler TS, et al. The Princeton IV consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2024. PubMed.
- Andersson DP, et al. Association of phosphodiesterase-5 inhibitors versus alprostadil with survival in men with coronary artery disease. J Am Coll Cardiol. 2021. PubMed.
- American Urological Association. Erectile Dysfunction (ED) Guideline.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.